Investing.com - InMed Pharmaceuticals reported on Friday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
InMed Pharmaceuticals announced earnings per share of $-4.060 on revenue of $320.79K. Analysts polled by Investing.com anticipated EPS of $-4.250 on revenue of $500K.
InMed Pharmaceuticals shares are down 90% from the beginning of the year and are trading at $3.000 , down-from-52-week-high.
InMed Pharmaceuticals follows other major Healthcare sector earnings this month
InMed Pharmaceuticals's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar